Skip to main content

Bristol-Myers Squibb Company(BMY-N)

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

PR Newswire - Sun Sep 17, 6:57PM CDT

INCHEON, South Korea, Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.


Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.